BXOS110 Injection in the Treatment of Acute Ischaemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT06322394

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Biocells (Beijing) Biotech Co.,Ltd (from the registry)
Registry
  • NCT NCT06322394
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06322394. Randomized; double masking; primary purpose treatment. Start 2024-02-07 (actual); primary completion 2025-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BXOS110 Injection in the Treatment of Acute Ischaemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
high-dose BXOS110
Intervention (Drug)
low-dose BXOS110
Intervention (Drug)
Placebo
Lead sponsor
Biocells (Beijing) Biotech Co.,Ltd (class: industry)

Record details

Record id
cardio:ct-nct06322394
Content hash
de8b626a9a56c0a0582e6c1b66d476e325793a6d36d95540ed69d1166dd899f3